ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.

Biotechnology

Health Care

Life Sciences

Medical Devices

Therapeutics

ProKidney Corp.

Bruce Culleton

Lauren Hartnett Twiss

Joy S. Alex

Elizabeth Lotz

Tierney Daigle

QC Director, Analytical Science And Technology (asat)

Carla Poulson

Kathleen Conde

Anu Biswas

Brian Buckley

James Coulston

Clarence W. Baker

Nancy Fuselli

McKenzie Christopher Pitts

Emily Butler

Todd Girolamo

Nikhil Pereira-Kamath

Clinical and Quality Assurance Team

Leadership Team

Manufacturing and Supply Chain

Directors and Senior Management

Research and Development

Human Resources

Teams at ProKidney Corp.